公开(公告)号：US20180111986A1

公开(公告)日：2018-04-26

申请号：US15534635

申请日：2015-12-11

Applicant: AMGEN INC. ,  UCB PHARMA S.A.

Inventor： Martyn Kim Robinson ,  Michael Stuart Ominsky ,  Xiaodong Li ,  Hua Zhu Ke

IPC: C07K16/22 ,  A61P19/08 ,  A61K39/395 ,  A61K45/06 ,  A61P19/10

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61P19/08 ,  A61P19/10 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.

公开(公告)号：US09321840B2

公开(公告)日：2016-04-26

申请号：US14309118

申请日：2014-06-19

Applicant: UCB PHARMA S.A. ,  BIOGEN IDEC MA INC.

Inventor： Linda C. Burkly ,  Janine L. Ferrant-Orgettas ,  Ellen A. Garber ,  Yen-Ming Hsu ,  Lihe Su ,  Frederick R. Taylor ,  Ralph Adams ,  Derek Thomas Brown ,  Andrew George Popplewell ,  Martyn Kim Robinson ,  Anthony Shock ,  Kerry Louise Tyson

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。

公开(公告)号：US20140030268A1

公开(公告)日：2014-01-30

申请号：US13934433

申请日：2013-07-03

Applicant: UCB PHARMA S.A.

Inventor： Martyn Kim Robinson

IPC: A61K39/395 ,  A61K33/42

CPC classification number: A61K39/3955 ,  A61K33/42 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/22 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

Abstract translation: 本发明涉及骨病的治疗。 特别地，本发明涉及使用剂量假期来帮助克服当将多种剂量的抗体给予受试者时随时间发展的抗硬化蛋白抗体的抗性。 通过给予受治疗的这样的给药假期，受试者随后可以显示对后续剂量的抗硬皮素抗体的增加的应答。 可以给予受试者一批至少两剂量的抗硬化蛋白酶抗体和给药假期的多个周期。 在某些情况下，可以监控受试者，以帮助确定何时给予假期。 此外，可以从抗硬化蛋白酶抗体给药假期期间对受试者进行不同的治疗。

公开(公告)号：US11851483B2

公开(公告)日：2023-12-26

申请号：US15534635

申请日：2015-12-11

Applicant: AMGEN INC. ,  UCB PHARMA, S.A.

Inventor： Martyn Kim Robinson ,  Michael Stuart Ominsky ,  Xiaodong Li ,  Hua Zhu Ke

IPC: A61K39/395 ,  C07K16/22 ,  A61P19/08 ,  A61P19/10 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61P19/08 ,  A61P19/10 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.

公开(公告)号：US09925260B2

公开(公告)日：2018-03-27

申请号：US13934433

申请日：2013-07-03

Applicant: UCB PHARMA S.A.

Inventor： Martyn Kim Robinson

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/22 ,  A61K45/06 ,  A61K33/42 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K33/42 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/22 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US08784823B2

公开(公告)日：2014-07-22

申请号：US13656922

申请日：2012-10-22

Applicant: UCB Pharma S.A. ,  Biogen Idec MA Inc.

Inventor： Linda C. Burkly ,  Janine L. Ferrant-Orgettas ,  Ellen A. Garber ,  Yen-Ming Hsu ,  Lihe Su ,  Frederick R. Taylor ,  Ralph Adams ,  Derek Thomas Brown ,  Andrew George Popplewell ,  Martyn Kim Robinson ,  Anthony Shock ,  Kerry Louise Tyson

IPC: C07K16/28 ,  A61K39/395 ,  A61P19/02 ,  A61P19/04

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。